Table 2 Risk management options given as percentages undertaken by women at baseline and in the 3 years post-testing according to carrier status and age

From: Predictive genetic testing for BRCA1/2 in a UK clinical cohort: three-year follow-up

  

3 year follow-up

 

Baseline

N =154

Age group

N =227

Carrier ( n =53)

Non-carrier ( n =101)

Mammography

 <35

29

81

22

 35–49

46

91

44

 >50

61

100

65

 Total

45

89

46

BRRM*

 <35

2

38

0

 35–49

2

38

0

 ⩾50

0

0

0

 Total

1

34

0

BRRO+

 <35

2

25

0

 35–49

10

54

3

 >50

30

40

7

 Total

13

43

3

Breast biopsy *

 <35

Not asked

19

9

 35–49

 

19

2

 ⩾50

 

20

6

 Total

 

19

5

Ovarian biopsy+

 <35

Not asked

13

0

 35–49

 

4

0

 >50

 

0

4

 Total

 

6

1

Ovarian US+

 <35

8

81

5

 35–49

32

75

16

 ⩾50

26

60

25

 Total

43

75

17

CBE

 <35

35

88

39

 35–49

48

81

51

 ⩾50

48

100

38

 Total

45

85

44

Tamoxifen

 <35

0

0

0

 35–49

2

6

0

 ⩾50

10

20

6

 Total

3

6

2

BrSE

 <35

85

81

100

 35–49

91

97

98

 ⩾50

83

100

88

 Total

88

91

95

  1. Figures exclude patients who have had BRRM (*) or BRRO (+) as appropriate.
Back to article page